<DOC>
	<DOCNO>NCT00003840</DOCNO>
	<brief_summary>RATIONALE : DTGM fusion protein may able locate cancer cell stop grow . PURPOSE : Phase I/II trial study effectiveness DTGM fusion protein treat patient recurrent refractory acute myeloid leukemia .</brief_summary>
	<brief_title>DTGM Fusion Protein Treating Patients With Recurrent Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose DTGM fusion protein patient recurrent refractory adult acute myeloid leukemia . II . Determine dose-limiting toxic effect regimen patient . III . Measure pharmacokinetics regimen patient . IV . Evaluate response rate maximum tolerate dose immune response patient treat regimen . V. Correlate vitro sensitivity leukemic blast regimen response rate patient . VI . Correlate tumor necrosis factor genetic polymorphism toxicity profile dose-limiting toxic effect regimen patient . OUTLINE : This dose-escalation study . Patients stratify accord serum level anti-DTGM antibody titer ( 2 mg/L less vs great 2 mg/L ) . Patients receive DTGM fusion protein IV 15 minute day 1-5 . Patients partial response eligible retreatment . Cohorts 3-6 patient receive escalate dos DTGM fusion protein maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional patient accrue receive treatment DTGM fusion protein MTD . Patients follow monthly disease progression . PROJECTED ACCRUAL : Approximately 60 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically , morphologically , cell surface marker confirm adult acute myeloid leukemia ( AML ) Recurrent refractory least 1 prior induction therapy OR Relapsed remission less 1 year duration Antecedent myelodysplasia evolve AML allow Ineligible allogeneic stem cell transplantation fail prior transplantation No CNS leukemia PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : At least 12 week Hematopoietic : WBC great 10,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Transaminases le 5 time upper limit normal Albumin least 3 g/dL Renal : Creatinine great 1.5 mg/dL Cardiovascular : Cardiac ejection fraction least 50 % normal No myocardial infarction within past 6 month No disseminate intravascular coagulation Pulmonary : FEV1 least 70 % normal Other : No uncontrolled infection No concurrent serious medical problem psychiatric disorder No prior severe penicillin allergy ( hive anaphylactic reaction ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No concurrent growth factor Chemotherapy : See Disease Characteristics Recovered prior chemotherapy Prior hydroxyurea lowdose cytarabine ( le 100 mg subcutaneously ) low blast count allow discontinue day 1 study therapy No concurrent antineoplastic chemotherapy Endocrine therapy : Concurrent corticosteroid allow , include antiemetic Radiotherapy : Recovered prior radiotherapy No concurrent radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
</DOC>